Mr. Roberto Lacorte serves as Vice Chairman, Managing Director and Vice President of Pharmanutra S.p.A. Between January 1995 and April 1996, Mr. Lacorte carried out military service with the Marines. Betwe...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Andrea Lacorte	Chairman & President	no data	€2.19m	Veri yok
Roberto Lacorte	Vice Chairman	no data	€1.92m	0.15% € 800.1k
Carlo Volpi	Delegate Advisor	no data	€1.77m	10.58% € 58.0m
Germano Tarantino	Scientific Director & Executive Director	13.8yrs	€586.16k	Veri yok
Marida Zaffaroni	Independent Director	no data	€41.00k	Veri yok
Alessandro Calzolari	Lead Independent Director	no data	€41.00k	Veri yok
Giovanna Zanotti	Independent Director	no data	€41.00k	Veri yok
Debora Mazzacherini	Standing Auditor	no data	Veri yok	Veri yok
Michele Giordano	President of Supervisory Board	1.8yrs	Veri yok	Veri yok
Pasquale Giovinazzo	Internal Member of Supervisory Board	1.8yrs	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PHN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Pharmanutra Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Second quarter 2024 earnings released: EPS: €0.67 (vs €0.19 in 2Q 2023)

Investors Interested In Pharmanutra S.p.A.'s (BIT:PHN) Earnings

First quarter 2024 earnings released: EPS: €0.27 (vs €0.56 in 1Q 2023)

Upcoming dividend of €0.85 per share

Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Pharmanutra S.p.A. to Report Fiscal Year 2023 Results on Mar 15, 2024

Third quarter 2023 earnings released: EPS: €0.26 (vs €0.48 in 3Q 2022)

Second quarter 2023 earnings released: EPS: €0.19 (vs €0.49 in 2Q 2022)

First quarter 2023 earnings released

Upcoming dividend of €0.80 per share at 1.6% yield

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Pharmanutra S.p.A. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million.

These 4 Measures Indicate That Pharmanutra (BIT:PHN) Is Using Debt Safely

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

PharmaNutra S.P.A. Announces European Union Authorises Marketing of CFAs as Novel Food

Pharmanutra (BIT:PHN) Could Easily Take On More Debt

Third quarter 2021 earnings released: EPS €0.39 (vs €0.18 in 3Q 2020)

Capital Allocation Trends At Pharmanutra (BIT:PHN) Aren't Ideal

Investor sentiment improved over the past week

Price target increased to €59.33

Pharmanutra (BIT:PHN) Will Be Hoping To Turn Its Returns On Capital Around

Price target increased to €50.67

Investor sentiment improved over the past week

Price target increased to €45.00

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

Upcoming dividend of €0.67 per share

Returns On Capital Signal Tricky Times Ahead For Pharmanutra (BIT:PHN)

Full year 2020 earnings released: EPS €1.45 (vs €0.87 in FY 2019)

Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?

Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?

Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?

Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?

Is Pharmanutra (BIT:PHN) A Risky Investment?

Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return

New 90-day high: €33.70

Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?

Market bids up stock over the past week

Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?

New 90-day high: €28.80

Third quarter 2020 earnings released: EPS €0.18

New 90-day high: €27.20

First half earnings released

First half earnings released

New 90-day low - €22.40

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş